Tips for Wegovy Success: What Actually Makes a Difference

The myth that the medicine does all the work, and why it matters that it doesn't

The most common misconception about Wegovy is that it operates independently of how you live. It doesn't. Semaglutide changes the signal, not the story: it tells your brain you are full sooner, keeps food in your stomach longer, and quiets a lot of the background noise around hunger. What it doesn't do is choose what fills the plate when the hunger signal is quieter.

In the STEP 1 trial (the main phase-3 study that informed Wegovy's UK licence) participants received structured behavioural counselling throughout the 68 weeks, not just a prescription. The STEP 1 paper published in the New England Journal of Medicine shows roughly 15% average weight loss; that figure comes from a population that was actively supported. Expecting the same result without any parallel lifestyle change sets an unfair benchmark.

The corrected picture: Wegovy is a powerful clinical tool, and it works considerably better when you treat the reduced appetite as an opportunity to build different habits rather than simply a mechanism that replaces them. That is not a motivational slogan, it is what the evidence reflects. If you want to explore how Wegovy compares with tirzepatide on this point, the Wegovy comparison page covers the trial data side by side.

Practical routines that support tolerability, especially around dose changes

Nausea is the side effect most people worry about, and it is also the one most influenced by behaviour. The GI effects of semaglutide peak in the first few days after each dose step and tend to ease considerably once your system settles, usually within one to two weeks. A few habits consistently make that window more manageable.

Eat slowly and stop before you feel full in the way you used to. The medicine already slows gastric emptying; eating quickly on top of that is a reliable recipe for discomfort. Smaller portions, more frequently, with less fat and fewer processed foods during the adjustment period tends to help. Alcohol amplifies nausea for many people in the early weeks. Keeping well hydrated matters more than it sounds, particularly if you experience loose stools or reduced appetite means you are drinking less without realising.

Injection routine is worth thinking about too. Lots of people keep their pen in the fridge door and inject on the same morning each week, before breakfast, so it becomes as automatic as any other weekly habit. Rotating sites (abdomen, thigh, upper arm) reduces local reactions. For the full storage and administration detail, always refer to the Patient Information Leaflet that comes with your pen; the guidance on semaglutide via NHS medicines pages is also a reliable plain-English reference. You can find additional practical questions answered on the nume FAQs page.

Protein, activity and the muscle question people don't ask until later

Weight loss from any method (including GLP-1 medicines) involves losing both fat and lean tissue. The proportion matters for long-term health, metabolic rate and how you feel. Wegovy does not automatically protect muscle mass; adequate protein and resistance activity do.

Most clinical dietitians suggest prioritising protein at each meal when appetite is reduced by a GLP-1 medicine, because total calorie intake drops and protein often gets squeezed out first. Practically: a source of protein at breakfast and lunch, before appetite fades, tends to work better than trying to eat it in the evening when you are already full. You don't need a gym membership (carrying shopping, bodyweight exercises, a short walk) the NHS Better Health lose weight guidance offers accessible baseline recommendations that pair well with medical treatment.

Strength activity also appears to improve how people feel on a GLP-1 medicine in general, possibly because the fatigue side effect responds to graduated movement better than rest does. It is worth discussing a basic activity plan with your prescriber or a dietitian rather than waiting until you are already well into treatment. For context on who is typically eligible to start Wegovy, the age and eligibility guidance page outlines what a prescriber considers.

What to do when progress slows, and what it usually means

A plateau is not a failure of the medicine or of you. Weight loss from Wegovy typically follows a curve: faster in the first three to six months, then a gradual slow-down as the body adapts. This is physiologically normal and is reflected in the trial timelines (the STEP 1 study ran 68 weeks for a reason). The temptation when a plateau arrives is to assume the medicine has stopped working. It usually hasn't.

Before escalating to a higher dose, it is worth reviewing a few things: calorie creep (portions gradually expanding as you adjust to smaller amounts), protein intake, hydration, sleep quality and stress levels, all of which affect the weight-loss response. If you have ever been unsure whether the product you have been dispensed is the same medicine under a different brand, the page covering the various names for Wegovy clears that up clearly. The practical Wegovy tips page goes into more granular detail on these factors.

If you are considering whether you are on the right treatment altogether, a guide to obtaining Wegovy through a legitimate UK pharmacy explains what a properly supervised prescription process looks like, which matters because getting clinical support at the plateau stage is exactly where good aftercare earns its place. Our weight-loss treatment overview also sets out the broader options. All dose changes at nume are reviewed by a prescriber; the clinical team page sets out who is doing that review. When you are ready to explore whether Wegovy is right for your situation, you can start a free consultation and a GPhC-registered prescriber will assess your case the same day, and if your pharmacist asks for a code for Wegovy when processing your prescription, that page explains exactly what to expect.